Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease - a case report

General Hospital Psychiatry

Volumn 33, Issue 3, 2011, Pages 301.e7-301.e8

  Wu, Yung Fu ^a   Kan, Yuk Shing ^b   Yang, Chen Hong ^b  

^a Beitou Armed Forces Hospital   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Bromocriptine; Dopamine; Neuroleptic malignant syndrome; Parkinson's disease

Indexed keywords

BICARBONATE; BROMOCRIPTINE; CREATINE KINASE; PARACETAMOL;

ABNORMAL BEHAVIOR; AGED; AGITATION; ARTERIAL GAS; ARTICLE; BODY TEMPERATURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; CRYSTALLOID; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAPHORESIS; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; EMERGENCY WARD; FLUID THERAPY; HUMAN; HYPERTENSION; HYPERTHERMIA; LEUKOCYTOSIS; MALE; METABOLIC ACIDOSIS; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; SINUS TACHYCARDIA; THORAX RADIOGRAPHY; VISUAL HALLUCINATION; WITHDRAWAL SYNDROME;

EID: 79956153816     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.11.013     Document Type: Article

References (13)

1. Anglin R.E., Rosebush P.I., Mazurek M.F. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ 2010, 182:E834-E838.
2. Rosebush P.I., Anglin R.E., Richards C., Mazurek M.F. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol 2008, 28:459-461.
3. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. 2000;18:317-325, x.
4. Keyser D.L., Rodnitzky R.L. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 1991, 151:794-796.
5. van Hilten J.J., Ramaker C.C., Stowe R., Ives N.J. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev 2007, CD002258.
6. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 68:685-690.
7. Gillman P.K. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 2010, 25:1780-1790.
8. Ananth J., Aduri K., Parameswaran S., Gunatilake S. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatr 2004, 16:219-228.
9. Strawn J.R., Keck P.E., Caroff S.N. Neuroleptic malignant syndrome. Am J Psychiatry 2007, 164:870-876.
10. Caroff S.N., Campbell E.C., Sullivan K.A. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother 2007, 7:423-431.
11. Delay J., Deniker P. Drug-induced extrapyramidal syndromes: diseases of the basal ganglia. Handbook of clinical neurology 1968, 248-266. North-Holland Publishing Co, Amsterdam. P.J. Vinken, G.W. Bruyn (Eds.).
12. Bhanushali M.J., Tuite P.J. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004, 22:389-411.
13. Bottoni T.N. Neuroleptic malignant syndrome: a brief review. Hosp Physician 2002, 15:58-63.